The asset manager has expanded its exchange-traded fund (ETF) range with the launch of biotech, small-cap and mid-cap equity funds.
T. Rowe Price has launched three actively managed equity exchange traded funds (ETFs), adding exposure to biotechnology, US small-cap stocks and US mid-cap equities. The Biotech ETF seeks long-term capital growth through investments in biotechnology companies The funds- the T. Rowe Price Biotech ETF (TDNA), T. Rowe Price Small-Cap ETF (TSEE) and T. Rowe Price Mid-Cap Equity Research ETF (TMID) began trading on Nasdaq on 17 September. The launches bring the firm's ETF lineup to 38 fund